Premium
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Author(s) -
Kang JuHee,
Korecka Magdalena,
Figurski Michal J.,
Toledo Jon B.,
Blennow Kaj,
Zetterberg Henrik,
Waligorska Teresa,
Brylska Magdalena,
Fields Leona,
Shah Nirali,
Soares Holly,
Dean Robert A.,
Vanderstichele Hugo,
Petersen Ronald C.,
Aisen Paul S.,
Saykin Andrew J.,
Weiner Michael W.,
Trojanowski John Q.,
Shaw Leslie M.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.05.003
Subject(s) - biomarker , alzheimer's disease neuroimaging initiative , biobank , neuroimaging , disease , medicine , amyloid beta , oncology , alzheimer's disease , psychology , neuroscience , bioinformatics , biology , biochemistry
We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ 1–42 ), t‐tau, and p‐tau 181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids. Methods Review publications authored or coauthored by ADNI Biomarker core faculty and selected non‐ADNI studies to deepen the understanding and interpretation of CSF Aβ 1–42 , t‐tau, and p‐tau 181 data. Results CSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non‐ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies. Discussion Further studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease‐modifying therapeutic trials.